HomeComparePABD vs JNJ

PABD vs JNJ: Dividend Comparison 2026

PABD yields 2.82% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PABD wins by $3.9K in total portfolio value
10 years
PABD
PABD
● Live price
2.82%
Share price
$62.92
Annual div
$1.77
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.9K
Annual income
$337.67
Full PABD calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — PABD vs JNJ

📍 PABD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPABDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PABD + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PABD pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PABD
Annual income on $10K today (after 15% tax)
$239.36/yr
After 10yr DRIP, annual income (after tax)
$287.02/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $416.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PABD + JNJ for your $10,000?

PABD: 50%JNJ: 50%
100% JNJ50/50100% PABD
Portfolio after 10yr
$22.0K
Annual income
$582.73/yr
Blended yield
2.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PABD
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PABD buys
0
JNJ buys
0
No recent congressional trades found for PABD or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPABDJNJ
Forward yield2.82%3.36%
Annual dividend / share$1.77$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$23.9K$20.0K
Annual income after 10y$337.67$827.78
Total dividends collected$3.1K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PABD vs JNJ ($10,000, DRIP)

YearPABD PortfolioPABD Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,982$281.60$10,676$355.77+$306.00PABD
2$12,039$289.02$11,407$389.39+$632.00PABD
3$13,178$296.12$12,198$426.53+$980.00PABD
4$14,404$302.93$13,056$467.62+$1.3KPABD
5$15,721$309.44$13,987$513.12+$1.7KPABD
6$17,137$315.65$14,998$563.56+$2.1KPABD
7$18,659$321.58$16,098$619.52+$2.6KPABD
8$20,292$327.22$17,295$681.69+$3.0KPABD
9$22,045$332.58$18,599$750.82+$3.4KPABD
10$23,926$337.67$20,022$827.78+$3.9KPABD

PABD vs JNJ: Complete Analysis 2026

PABDStock

The iShares Paris-Aligned Climate Optimized MSCI World ex USA ETF (“the Fund”) seeks to track the investment results of an index composed of large- and mid-capitalization developed market equities, excluding the U.S., that is designed to be compatible with the objectives of the Paris Agreement by, in aggregate, following a decarbonization trajectory, reducing exposure to climate-related transition and physical risks and increasing exposure to companies favorably positioned for the transition to a low-carbon economy.

Full PABD Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this PABD vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PABD vs SCHDPABD vs JEPIPABD vs OPABD vs KOPABD vs MAINPABD vs ABBVPABD vs MRKPABD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.